The College of Social Work (CoSW) at the University of Kentucky will share in close to $1 billion in federal grants aimed at combating the nation's opioid epidemic.
The University of Kentucky College of Pharmacy will host its tenth annual Therapeutics, Outcomes, Discovery & Delivery (TODD) Symposium from 8 a.m. – 5:30 p.m. on Tuesday, Nov. 12, 2019, in room 124 of the Lee T. Todd, Jr. Building.
Dr. Michelle Lofwall, UK College of Medicine, is one of three national addiction physician experts who led a team of healthcare professionals in developing a new core curriculum designed to educate primary care providers on the prevention, assessment and treatment of substance use disorders (SUD) throughout the continuum of care.
The University of Kentucky has launched a new website for information, news-related updates and excerpts regarding their recently awarded $87 million HEALing Communities Study cooperative agreement.
Few regions have been hit harder by the drug epidemic than Kentucky and need increased access to evidence-based treatment for substance use disorders. The University of Kentucky Department of Psychiatry saw that need and developed a new clinic to better support patients.
Faculty from the Dept of Psychology in the College of Arts & Sciences and Behavioral Science in the College of Medicine have received two, five-year Research Project Grants from the NIH to study neurobehavioral processes involved in drug use disorders.
As a busy trauma surgeon, Dr. Phillip Chang saw his fair share of patients who were dealing with significant pain. As per the standards then, these patients would receive opioids for pain management. Most recovered and were weaned off the medication as planned.
America’s Essential Hospitals, a national trade association, has recognized UK HealthCare for its work to develop safer opioid usage practices within an academic health system.
Jennifer Havens has spent the past decade studying the transmission of infectious disease and advocating for the expansion of harm reduction programs. That work entails understanding the link between two health burdens facing the nation, the opioid crisis and cancer.
In 2017, Dr. Linda Dwoskin applied to NIDA's Grand Opportunity for Medications Development program for support to continue her quest to develop the first-ever medication to reduce craving and relapse in methamphetamine use disorder.
